Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Lynch

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Cancer Letters|April 2, 2008
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase DLaurens A van Meeteren, Volker Brinkmann, Jean Sébastien Saulnier-Blache, et al.
Circulation Research|March 8, 2008
Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophagesJeniter E Hughes, Suseela Srinivasan, Kevin R Lynch, et al.
Oncotarget|October 23, 2018
Correction: Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cellsMateusz Adamiak, Lakshman Chelvarajan, Kevin R Lynch, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acidWebster L Santos, Brian H Heasley, Renata Jarosz, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonistBrian H Heasley, Renata Jarosz, Karen M Carter, et al.
Journal of Medicinal Chemistry|April 14, 2017
Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo ActivityElizabeth S Childress, Yugesh Kharel, Anne M Brown, et al.
Molecular Carcinogenesis|February 11, 2009
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cellsCristoforo G Gaetano, Nasser Samadi, Jose L Tomsig, et al.
Analytical Biochemistry|January 11, 2011
A rapid assay for assessment of sphingosine kinase inhibitors and substratesYugesh Kharel, Thomas P Mathews, Andrew J Kennedy, et al.
Diabetes|November 16, 2007
Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69Suseela Srinivasan, David T Bolick, Dmitriy Lukashev, et al.
Pharmacological Reviews|May 31, 2002
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclatureJerold Chun, Edward J Goetzl, Timothy Hla, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Cancer Letters|April 2, 2008
Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase DLaurens A van Meeteren, Volker Brinkmann, Jean Sébastien Saulnier-Blache, et al.
Circulation Research|March 8, 2008
Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophagesJeniter E Hughes, Suseela Srinivasan, Kevin R Lynch, et al.
Oncotarget|October 23, 2018
Correction: Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cellsMateusz Adamiak, Lakshman Chelvarajan, Kevin R Lynch, et al.
Bioorganic & Medicinal Chemistry Letters|June 5, 2004
Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acidWebster L Santos, Brian H Heasley, Renata Jarosz, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonistBrian H Heasley, Renata Jarosz, Karen M Carter, et al.
Journal of Medicinal Chemistry|April 14, 2017
Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo ActivityElizabeth S Childress, Yugesh Kharel, Anne M Brown, et al.
Molecular Carcinogenesis|February 11, 2009
Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cellsCristoforo G Gaetano, Nasser Samadi, Jose L Tomsig, et al.
Analytical Biochemistry|January 11, 2011
A rapid assay for assessment of sphingosine kinase inhibitors and substratesYugesh Kharel, Thomas P Mathews, Andrew J Kennedy, et al.
Diabetes|November 16, 2007
Sphingosine-1-phosphate reduces CD4+ T-cell activation in type 1 diabetes through regulation of hypoxia-inducible factor short isoform I.1 and CD69Suseela Srinivasan, David T Bolick, Dmitriy Lukashev, et al.
Pharmacological Reviews|May 31, 2002
International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclatureJerold Chun, Edward J Goetzl, Timothy Hla, et al.
Pageof 10